Alnylam Pharmaceuticals | ALNY - Ebit


Alnylam Pharmaceuticals reported $29.4M in EBIT for its fiscal quarter ending in December of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.48B 343M Sep/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sanofi EUR 3.74B 2.23B Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Takeda JPY 257.49B 568.56B Dec/2025
Tectonic Therapeutic USD -22.33M 4.03M Jun/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -47.52M 24.69M Sep/2025